STOCK TITAN
  1. Home
  2. News
  3. ATOS

Atossa Therapeutics, Inc. - ATOS STOCK NEWS

Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.

Atossa Therapeutics, Inc. (NASDAQ: ATOS) is a pioneering biopharmaceutical company headquartered in Seattle, Washington. Established in 2009, Atossa focuses on developing innovative and proprietary medicines targeting unmet medical needs in oncology, with a particular emphasis on breast cancer. The company is currently in the clinical stage, advancing several key programs designed to improve cancer treatment and prevention.

Atossa's core program is the development of (Z)-endoxifen, a potent metabolite of tamoxifen, crucial for treating and preventing breast cancer. Currently, (Z)-endoxifen is in Phase II clinical trials aimed at various breast cancer conditions, including estrogen receptor-positive breast cancer, ductal carcinoma in situ (DCIS), and mammographic breast density. The company is also exploring its efficacy in combination therapies with drugs like abemaciclib, a CDK 4/6 inhibitor.

In addition to breast cancer, Atossa has ventured into COVID-19 therapeutics with two potential treatments: AT-H201 for improving lung function in severe COVID-19 patients and AT-301, a nasal spray for at-home use.

Recently, Atossa has achieved several milestones, including the successful dosing of the first patient in the RECAST DCIS study, full enrollment of its Phase II Karisma-Endoxifen trial, and promising preliminary data from the 40mg cohort in the EVANGELINE study. The company also regained compliance with Nasdaq's minimum bid price requirement.

Atossa's collaborative efforts include partnerships with Quantum Leap Healthcare Collaborative and Weill Cornell Medicine, advancing studies in combination therapies and breast cancer risk assessment through innovative AI models. With a strong financial position, including $84 million in cash and no debt as of Q1 2024, Atossa is well-positioned to continue its groundbreaking work in oncology.

News

Atossa Therapeutics Issues Letter to Shareholders

Rhea-AI Summary
Atossa Therapeutics, a clinical stage biopharmaceutical company (Nasdaq: ATOS), announces significant progress in 2023, with four Phase 2 trials investigating proprietary (Z)-endoxifen and important research with Weill Cornell Medicine. The Phase 2 Karisma-Endoxifen trial reached full enrollment in November 2023, studying the effect of (Z)-endoxifen in premenopausal women with measurable breast density.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
none
-
News

Physician-Scientist Steven Quay Speaks to Victor Davis Hanson about lockdowns, mRNA vaccines, and the origins of the COVID virus

Rhea-AI Summary
Dr. Steven Quay, MD, PhD discusses cost-benefit analysis, mRNA vaccines, and SARS-CoV-2 origins in a one-hour podcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
covid-19
-
News

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) appoints Dr. Arezoo Mirad as Senior Medical Director, aiming to accelerate the (Z)-endoxifen development program. With four ongoing Phase 2 trials and important data expected in 2024, the company anticipates improving the standard of care for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
management
News

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) has reached full enrollment in the Karisma-Endoxifen clinical trial, a Phase 2 study investigating (Z)-endoxifen in premenopausal women with measurable mammographic breast density (MBD). The trial aims to measure reduction in MBD as a proxy for therapy response. The study is expected to provide data in the second half of 2024, with potential implications for breast cancer prevention and novel treatments like (Z)-endoxifen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
clinical trial
-
News

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) achieved significant enrollment milestones in ongoing Phase 2 clinical trials for (Z)-endoxifen, including a study in DCIS. The company ended Q3 2023 with $94.0 million in cash and cash equivalents. Key developments include 80% enrollment in ongoing trials, initiation of a new Phase 2 study, approval from Health Canada for a clinical trial, and a research agreement with Weill Cornell Medicine. Financial results show a decrease in operating expenses for Q3 2023 compared to Q3 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
earnings
-
News

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced the appointment of Jonathan Finn, CFA, to its board of directors. Finn brings over 25 years of financial industry experience, specializing in early to mid-stage biotech and technology companies. His appointment is expected to accelerate growth and commercialize assets, with critical data readouts expected next year. With four ongoing Phase 2 trials and a strong multi-year cash position, Atossa is well positioned to deliver on its vision of fundamentally changing the breast cancer treatment paradigm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.04%
Tags
management
News

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Rhea-AI Summary
Quantum Leap Healthcare Collaborative (QLHC) has launched a Phase 2 platform study called RECAST DCIS to prevent the progression of DCIS to breast cancer. The study is evaluating three investigational endocrine therapy arms: (Z)-endoxifen, HAVAH T+Ai™, and ORSERDU®. The trial aims to reduce unnecessary surgeries and overtreatment of DCIS patients by offering up to six months of endocrine therapy and long-term active surveillance. Each investigational agent arm is expected to enroll up to 110 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
clinical trial
-
News

Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer

Rhea-AI Summary
Cognito Therapeutics appoints Greg Weaver as CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
management
-
News

Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later

Rhea-AI Summary
Dr. Steven Quay calls for nutritional guidelines for adolescent girls to reduce future breast cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
News

Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment

Rhea-AI Summary
Atossa Therapeutics working on promising drug for breast cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
none

FAQ

What is the current stock price of Atossa Therapeutics (ATOS)?

The current stock price of Atossa Therapeutics (ATOS) is $0.9517 as of January 7, 2025.

What is the market cap of Atossa Therapeutics (ATOS)?

The market cap of Atossa Therapeutics (ATOS) is approximately 120.9M.

What is Atossa Therapeutics' primary focus?

Atossa Therapeutics primarily focuses on developing innovative medicines for oncology, specifically targeting breast cancer.

What is (Z)-endoxifen?

(Z)-endoxifen is an active metabolite of tamoxifen, currently in Phase II trials, developed to treat and prevent breast cancer.

What are some of Atossa's recent achievements?

Recent achievements include dosing the first patient in the RECAST DCIS study, full enrollment of the Karisma-Endoxifen trial, and promising data from the EVANGELINE study.

Who are Atossa's key collaborators?

Atossa collaborates with Quantum Leap Healthcare Collaborative and Weill Cornell Medicine to advance studies in oncology and innovative treatment methods.

What financial condition is Atossa in?

As of Q1 2024, Atossa has $84 million in cash and no debt, positioning it well for continued research and development.

What other conditions is Atossa targeting besides breast cancer?

Atossa is also developing treatments for COVID-19, including AT-H201 for severe cases and AT-301, a nasal spray for at-home use.

Where is Atossa Therapeutics headquartered?

Atossa Therapeutics is headquartered in Seattle, Washington.

When was Atossa Therapeutics founded?

Atossa Therapeutics was founded in 2009.

What is the significance of (Z)-endoxifen Phase II trials?

These trials are crucial for developing effective treatments for various breast cancer conditions, potentially improving patient outcomes significantly.

How does Atossa contribute to breast cancer risk assessment?

Atossa supports innovative AI-driven models like the Profound AI Model to improve breast cancer risk assessment and prevention strategies.
Stock ATOS logo
Atossa Therapeutics, Inc.

Nasdaq:ATOS

ATOS Rankings

#4319 Ranked by Market Cap
N/A Ranked by Dividends

ATOS Stock Data

120.90M
125.73M
0.06%
28.13%
6.52%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SEATTLE